nach oben

Digestive Diseases and Sciences

Erschienen in:

01.02.2013 | Original Article

Are Biopsy Specimens Predictive of HER2 Status in Gastric Cancer Patients?

verfasst von: M. Pirrelli, M. L. Caruso, M. Di Maggio, R. Armentano, A. M. Valentini

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Trastuzumab has been recently proposed as a treatment for patients with HER2-positive advanced/metastatic gastric cancer (GC). Since most patients have inoperable disease at diagnosis, accurate assessment of HER2 status on biopsy specimens is essential to select the patients who may benefit from therapy.

Aim

The aim of this study is to establish whether HER2 status assessed on biopsy material could be reliable for treatment decisions using anti-HER2 agents.

Methods

The HER2 status was evaluated in 61 consecutive pairs of biopsy and surgical GCs samples by immunohistochemistry and chromogenic in situ hybridization.

Results

The overall concordance of HER2 status between biopsy and surgical specimens was 91.8 % with a predictive positive value of 71.4 % and a negative predictive value of 94.4 %. Of five discordant cases, there were three negative and two positive false biopsy results. All the false negative cases showed heterogeneous expression of HER2 protein in surgical samples. Two cases displayed overexpression of the receptors without corresponding gene amplification.

Conclusions

HER2 status as evaluated on biopsy samples is a fairly good predictor of HER2 status of surgically-excised GCs. The most important influence for discordant results is tumor heterogeneity. However, HER2 overexpression, especially without coexisting gene amplification, may only be a temporary change in a tumor population. This may explain those cases with positive HER2 evaluation on biopsy material and a negative result on corresponding surgical specimen.

Kamagar F, Dores GM, Anderson WF. Pattern of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–2150.CrossRef

Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present and future. J Gastroenterol. 2008;43:256–264.PubMedCrossRef

Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilo-Dalton glycoprotein with tyrosine kinase activity. Science. 1986;232:1644–1646.PubMedCrossRef

Coussens L, Yang-feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132–1339.PubMedCrossRef

Kaptain S, Tan LK, Chen B. HER2/neu and breast cancer. Diagn Mol Pathol. 2001;10:139–152.PubMedCrossRef

Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F. HER2/neu protein expression in colorectal cancer. BMC Cancer. 2006;6:123.PubMedCrossRef

Eltze E, Wulfing C, Von Struensee D, Piechota H, Buerger H, Hertle L. HER2/neu co-expression in invasive bladder cancer. Int J Oncol. 2005;26:1525–1531.PubMed

Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992;47:179–185.PubMedCrossRef

Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78:26–33.PubMedCrossRef

10.

Gravalos C, Jimeno A. HER2 in gastric cancer : a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–1529.PubMedCrossRef

11.

Reichelt U, Duesedau P, Tsourlakis MCh, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20:120–129.PubMedCrossRef

12.

Hofmann M, Stoss O, Shi D, et al. Assessment of HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.PubMedCrossRef

13.

Marx AH, Tharun L, Muth J, et al. Her-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40:769–777.PubMedCrossRef

14.

Grabsh H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value—conclusions from 924 cases of two indipendent series. Cell Oncol. 2010;32:57–65.

15.

Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011;104:1372–1376.PubMedCrossRef

16.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.PubMedCrossRef

17.

Tanner M, Gancberg BA, Leo AD, et al. Chromogenic in situ hybridization: a practical alternative for fluorescece in situ hybridization to detect HER2/neu oncogene in archival breast cancer samples. Am J Pathol. 2000;157:1467–1472.PubMedCrossRef

18.

Zhao J, Wu R, Au A, et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002;15:657–665.PubMedCrossRef

19.

Peanault-Llorca F, Chenard MP, Bouchè O, et al. HER2 et cancer gastrique. Recommandations pour la pratique clinique en 2011. Ann Pathol. 2011;31:78–87.CrossRef

20.

Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostic in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299–307.PubMedCrossRef

21.

Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with Trastuzumab. Breast Cancer Res Treat. 2005;93:3–11.PubMedCrossRef

22.

Press M, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598–6607.PubMedCrossRef

23.

Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HERE2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006;15:65–71.PubMed

24.

Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011;59:832–840.PubMedCrossRef

25.

Yang J, Luo H, Li J, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys. 2012;62:221–228.PubMedCrossRef

26.

Dowsett M, Bartlett J, Ellis I, et al. Correlation between immunohistochemistry (Herceptest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418–423.PubMedCrossRef

27.

Lal P, Salazar P, Hudis C, Ladanyi M, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization. A single institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 2004;121:631–636.PubMedCrossRef

28.

Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–6487.PubMedCrossRef

29.

Lemoine NR, Jain S, Silvestre F, et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer. 1991;64:79–83.PubMedCrossRef

30.

Kameda T, Yasui W, Yoshida K, et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res. 1990;50:8002–8029.PubMed

31.

Cottu PH, Asselah J, Lae M, et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol. 2008;19:595–597.PubMedCrossRef

32.

Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer. Arch Pathol Lab Med. 2009;133:611–612.PubMed

33.

Lebeau A, Turzynski A, Braun S, et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol. 2010;28:3264–3270.PubMedCrossRef

34.

Tamaki K, Sasano H, Ishida E, et al. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci. 2010;101:2074–2079.PubMedCrossRef

35.

Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Oamura RY. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. BMC Cancer. 2010;10:534.PubMedCrossRef

36.

Arnedos M, Nerurkar A, Osin P, A’Hern R, Smith IE, Dowsett M. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol. 2009;20:1948–1952.PubMedCrossRef

37.

Usami S, Moriya T, Amari M, et al. Reliability of prognostic factors in brest carcinoma determined by core needle biopsies. Jpn J Clin Oncol. 2007;37:250–255.PubMedCrossRef

38.

Yan SY, Hu Y, Fan JG, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011;17:1501–1506.PubMedCrossRef

39.

Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323–1333.PubMedCrossRef

40.

Kim MA, Lee H-J, Yang H-K, Bang Y-J, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59:822–831.PubMedCrossRef

41.

Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of ERBB2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93:552–556.PubMedCrossRef

42.

Rossi E, Villanacci V, Basotti G, et al. TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma. Histopathology. 2010;57:81–89.PubMedCrossRef

Titel: Are Biopsy Specimens Predictive of HER2 Status in Gastric Cancer Patients?
verfasst von: M. Pirrelli
M. L. Caruso
M. Di Maggio
R. Armentano
A. M. Valentini
Publikationsdatum: 01.02.2013
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 2/2013
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-012-2357-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aim

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Thrombocytopenia in Patients with Chronic Liver Disease: What’s in a Name?

CD34+ Hematopoietic Stem Cells Mobilization, Paralleled with Multiple Cytokines Elevated in Patients with HBV-Related Acute-on-Chronic Liver Failure

Can Cap-Assisted Colonoscopy Be a Savior for Right Side Interval Cancer?

Long-Term Outcomes and Prognostic Factors for Patients with Endoscopy-Negative Iron Deficiency

Fish Omega-3 Fatty Acids Induce Liver Fibrosis in the Treatment of Bile Duct-Ligated Rats